Results 121 to 130 of about 26,025 (223)

Mitochondrial reprogramming in lung cancer: a therapeutic vulnerability and a strategy for reversing drug resistance

The Journal of Pathology, Volume 269, Issue 2, Page 149-163, June 2026.
Abstract The conceptualization of mitochondria, previously restricted to their function as cellular ‘powerhouses’, has evolved to recognize their function as central coordinating hubs for the orchestration of cancer cell metabolism, signaling, and fate determination.
Woo Hyun Park
wiley   +1 more source

Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

European Journal of Haematology, Volume 116, Issue 6, Page 845-849, June 2026.
ABSTRACT Introduction Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V).
Rebecca Tidswell, Carolyn Owen, Mona Shafey, Sarah Perry, Nanette Cox‐Kennett, Russell Sterrett, Anthea Peters, Robert Puckrin   +7 more
wiley   +1 more source

Cost‐Effectiveness of Venetoclax‐Based Treatment in Treatment‐Naïve Fit Patients With CLL Without TP53 Aberrations

European Journal of Haematology, Volume 116, Issue 6, Page 873-882, June 2026.
ABSTRACT The GAIA‐CLL13 trial showed that venetoclax‐obinutuzumab (Ven‐O) based regimens, with or without ibrutinib, offer superior efficacy compared to chemoimmunotherapy (CIT) with regards to progression free survival (PFS) in fit, treatment‐naïve (TN) CLL patients. However, their higher costs warrant a cost‐effectiveness evaluation.
Lars Holger Ehlers, Mark‐David Levin, Marjolein van der Klift, Morten Berg Jensen, Hoa Thi Tuyet Tran, Arnon P. Kater, Carsten Utoft Niemann   +6 more
wiley   +1 more source

Inhibition of NRF2 enhances the acute myeloid leukemia cell death induced by venetoclax via the ferroptosis pathway

Cell Death Discovery
Venetoclax, an inhibitor that selectively targets B cell lymphoma-2 (BCL-2) that has been approved for treating adult acute myeloid leukemia (AML) in combination with hypomethylating agents.
Xibao Yu, Yan Wang, Jiaxiong Tan, Yuchen Li, Pengyue Yang, Xuan Liu, Jing Lai, Yue Zhang, Letong Cai, Yinfeng Gu, Ling Xu, Yangqiu Li   +11 more
doaj   +1 more source

Low molecular weight compounds from mushrooms as potential Bcl-2 inhibitors: docking and virtual screening studies [PDF]

, 2016
Mestrado com dupla diplomação com o Institut Superieur de Biotechnologie de MonastirMushrooms have the ability to promote apoptosis in tumor cell lines, but the mechanism of action is not quite well understood. Inhibition of the interaction between Bcl-2
Khelifa, Sabrine
core  

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, Volume 116, Issue 6, Page 759-770, June 2026.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy

Cancer, Volume 132, Issue 10, 15 May 2026.
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek, Courtney D. DiNardo, Sanam Loghavi, Farhad Ravandi, Gautam Borthakur, Naval G. Daver, Tapan M. Kadia, Elias Jabbour, Andrew Dunbar, Guilin Tang, Nicholas J. Short, Fadi G. Haddad, Hussein A. Abbas, Eitan Kugler, Abhishek Maiti, Ghayas C. Issa, Koichi Takahashi, Kapil Bhalla, Naveen Pemmaraju, Yesid Alvarado, Elizabeth J. Shpall, Uday Popat, Jeremy Ramdial, Richard E. Champlin, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Jayastu Senapati   +26 more
wiley   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, Volume 13, Issue 26, 8 May 2026.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia

American Journal of Hematology, Volume 101, Issue 5, Page 1019-1024, May 2026.
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Somedeb Ball, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Melissa A. Fischer, Zhiguo Zhao, Kateryna Fedorov, Ashwin Kishtagari, Sanjay R. Mohan, Gregory D. Ayers, Michael T. Byrne, Michael R. Savona   +11 more
wiley   +1 more source

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

Blood Cancer Journal
Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively
Y. Sawalha, S. Sarosiek, R. L. Welkie, S. Seif, S. Thapa, S. Zanwar, K. Cahill, R. Treitman, H. Shah, S. Arora, G. Pongas, A. Winter, A. Major, P. A. Riedell, M. L. Palomba, P. Kapoor, A. Grajales-Cruz, K. H. Shain, S. K. Thomas, J. J. Castillo   +19 more
doaj   +1 more source